单价与二价mRNA疫苗在6月龄至5岁儿童中预防COVID-19相关急诊和紧急护理就诊的有效性——VISION网络,美国,2022年7月至2023年6月
在VISION网络评估6月龄至5岁儿童中mRNA COVID-19疫苗对急诊/紧急护理就诊的有效性。完成2剂单价Moderna后疫苗有效性为29%(95%CI=12%-42%),完成3剂单价Pfizer-BioNTech后为43%(95%CI=17%-61%),至少1剂二价疫苗后为80%(95%CI=42%-96%)。所有儿童应及时接种推荐的新冠疫苗。
要点
- 6月龄至5岁儿童完成2剂单价Moderna后,急诊/紧急护理就诊疫苗有效性为29%(95%CI=12%-42%)。
- 6月龄至4岁儿童完成3剂单价Pfizer-BioNTech后,疫苗有效性为43%(95%CI=17%-61%)。
- 至少1剂二价疫苗后疫苗有效性为80%(95%CI=42%-96%)。
核心结论
- 单价mRNA疫苗对6月龄至5岁儿童COVID-19相关急诊/紧急护理就诊有中等保护作用,二价疫苗显示较高保护作用。
- 所有儿童应及时接种推荐的新冠疫苗,符合条件时立即开始接种。
研究设计与样本
- 在VISION网络内进行的疫苗有效性评估,纳入2022年7月4日至2023年6月17日期间有COVID-19样疾病的6月龄至5岁儿童。
- 分析分别针对接种2剂单价Moderna、3剂单价Pfizer-BioNTech以及至少1剂二价疫苗的儿童,并与未接种儿童比较。
主要发现
- 6月龄至5岁儿童接种2剂单价Moderna后≥14天(中位100天,IQR=63-155天)对急诊/紧急护理就诊的疫苗有效性为29%(95%CI=12%-42%)。
- 6月龄至4岁儿童接种3剂单价Pfizer-BioNTech后≥14天(中位75天,IQR=40-139天)的疫苗有效性为43%(95%CI=17%-61%)。
- 6月龄至5岁儿童接种至少1剂二价疫苗后中位58天(IQR=32-83天)的疫苗有效性为80%(95%CI=42%-96%)。
关键数值与推荐
- 2剂单价Moderna疫苗有效性29%(95%CI=12%-42%),评估时间≥14天 after dose 2。
- 3剂单价Pfizer-BioNTech疫苗有效性43%(95%CI=17%-61%),评估时间≥14天 after dose 3。
- 至少1剂二价疫苗有效性80%(95%CI=42%-96%),评估时间中位58天。
临床怎么用
- 所有儿童应及时接种推荐的新冠疫苗,包括在符合条件时立即开始COVID-19疫苗接种。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On June 19, 2022, the original monovalent mRNA COVID-19 vaccines were approved as a primary series for children aged 6 months-4 years (Pfizer-BioNTech) and 6 months-5 years (Moderna) based on safety, immunobridging, and limited efficacy data from clinical trials. On December 9, 2022, CDC expanded recommendations for use of updated bivalent vaccines to children aged ≥6 months. mRNA COVID-19 vaccine effectiveness (VE) against emergency department or urgent care (ED/UC) encounters was evaluated within the VISION Network during July 4, 2022-June 17, 2023, among children with COVID-19-like illness aged 6 months-5 years. Among children aged 6 months-5 years who received molecular SARS-CoV-2 testing during August 1, 2022-June 17, 2023, VE of 2 monovalent Moderna doses against ED/UC encounters was 29% (95% CI = 12%-42%) ≥14 days after dose 2 (median = 100 days after dose 2; IQR = 63-155 days). Among children aged 6 months-4 years with a COVID-19-like illness who received molecular testing during September 19, 2022-June 17, 2023, VE of 3 monovalent Pfizer-BioNTech doses was 43% (95% CI = 17%-61%) ≥14 days after dose 3 (median = 75 days after dose 3; IQR = 40-139 days). Effectiveness of ≥1 bivalent dose, comparing children with at least a complete primary series and ≥1 bivalent dose to unvaccinated children, irrespective of vaccine manufacturer, was 80% (95% CI = 42%-96%) among children aged 6 months-5 years a median of 58 days (IQR = 32-83 days) after the dose. All children should stay up to date with recommended COVID-19 vaccines, including initiation of COVID-19 vaccination immediately when they are eligible.
引用
- Link-Gelles R, Ciesla AA, Rowley EAK, et al. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months-5 Years - VISION Network, United States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37590187. doi:10.15585/mmwr.mm7233a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。